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argued that complex molecular changes might be easier to
access in tumour samples than in CTCs [4]. Ross and
co-workers are to be congratulated for broadening our
knowledge base for further development of patient-centred
bladder cancer trials.
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Experts’ summary:
Grams et al report results obtained during follow-up of seven
population cohorts for 4–16 yr to estimate the lifetime risk of
end-stage renal disease (ESRD) for individuals who do not
donate a kidney. The study utilized data from more than
31 million person-years of follow-up, and 15-yr projections
were then compared to the risk observed in US kidney donors.
The risk projections varied according to race and sex, and
the 15-yr risk observed in kidney donors was 3.5 to 5.3 times
as high as the risk projected for the general population.
The authors developed an online tool that includes ten
health characteristics that can help to estimate a person’s
ESRD risk to allow careful selection of living kidney donors.
Experts’ comments:
Transplantation execution and efficacy are constantly increas-
ing worldwide thanks to better national and international
networks and to technological progress. In 2013, 78 952 renal
transplants were recorded by the Global Observatory on
Donation and Transplantation, of which 41.6% were derived
from a living donor. In most countries, especially in Africa,
Asia, and the Middle East, the number of transplantations
from living donors greatly exceeds the number from dead
donors (up to 80%) [1].
Considering the exponential growth of living donor
transplantation, the guiding principles of the World Health
Organization (WHO) state that ‘‘Live donors should be
informed of the probable risks, benefits and consequences
of donation in a complete and understandable fashion’’
[2]. Therefore, an accessible tool for estimating ESRD risk is
essential to fulfill the WHO principles concerning informa-
tion for subjects who might donate a kidney.
Furthermore, thresholds for acceptable risks in donors
vary among transplant centers and clinicians, and there
has already been a call for a universally accepted donor-
centered tool [3].
A donor-centered model of risk assessment would
integrate the donor’s will with an objective projection of
risks to reach a truly shared decision about donation
eligibility.
It is our hope that an accessible, internationally recog-
nized tool, such as the one presented by Grams et al, could be
established. We believe that their findings are extremely
important, as the tool could (1) help to minimize the number
of living kidney donors in whom ESRD might ultimately
develop and (2) support donation among people whose long-
term risk was previously misunderstood (eg, donors older
than 65 yr, even with a low estimated glomerular filtration
rate or mild hypertension, who might never develop ESRD
after donating a kidney). This could save more lives not only
among those who need a transplant but also among donors
who might develop ESRD. By possibly enhancing the number
of donors, the tool could help in fulfilling the most admirable
aim, to improve the lives of others.
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